VPHIF OTC
Valeo Pharma Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: -0.0%
1Y: -99.8%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$54M
+94.3% ▲
5Y CAGR: +65.2%
Gross Profit
$13M
+108.2% ▲
5Y CAGR: +73.5%
Operating Income
-$17M
+12.1% ▲
Net Income
-$28M
-8.0% ▼
EPS (Diluted)
$-0.32
+0.0% ▲
EBITDA
-$11M
+29.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $7M | $7M | $14M | $28M | $54M |
| YoY Growth | +50.1% | +13.6% | +81.5% | +104.7% | +94.3% |
| Cost of Revenue | $5M | $6M | $10M | $21M | $41M |
| Gross Profit | $1M | $1M | $4M | $6M | $13M |
| Gross Margin | 21.3% | 18.5% | 29.2% | 22.6% | 24.3% |
| R&D Expenses | $8K | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5M | $5M | $16M | $25M | $29M |
| Operating Expenses | $5M | $6M | $17M | $28M | $30M |
| Operating Income | -$4M | -$4M | -$13M | -$20M | -$17M |
| Operating Margin | -53.9% | -58.1% | -94.5% | -70.7% | -32.0% |
| Interest Expense | $110K | $598K | $1M | $6M | $14M |
| Income Before Tax | -$4M | -$5M | -$14M | -$27M | -$28M |
| Tax Expense | $326K | $0 | $0 | -$1M | $0 |
| Net Income | -$4M | -$5M | -$14M | -$26M | -$28M |
| Net Margin | -55.0% | -63.7% | -105.0% | -92.8% | -51.6% |
| EPS (Diluted) | $-0.07 | $-0.08 | $-0.20 | $-0.32 | $-0.32 |
| EBITDA | -$3M | -$4M | -$11M | -$16M | -$11M |
| Shares Outstanding | 50M | 58M | 70M | 81M | 86M |